Quantcast

Latest Anthracyclines Stories

2008-10-15 09:00:47

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion regarding ZIOPHARM's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma (STS). In the European Union (EU), products targeted to treat life-threatening or very serious conditions that affect fewer than five in 10,000 people are eligible for orphan...

2008-09-24 15:01:01

CELSION CORPORATION (NASDAQ: CLSN) announced today that its global Phase III Primary Liver Cancer trial is proceeding as planned. In addition to the receipt of FDA agreement in January of 2008 for our pivotal Phase III Primary Liver Cancer trial in the United States, the Company reports that it has obtained regulatory approval to conduct its study titled "A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox(R) (Thermally Sensitive Liposomal...

2008-09-16 09:00:15

REDWOOD CITY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. "The treatment of soft tissue sarcomas continues to be a difficult challenge. New therapeutic and novel agents are required to improve the...

2008-09-09 09:00:09

Ortho Biotech Products, a biopharmaceutical company, has submitted a supplemental new drug application to the FDA for the combination of Doxil and Taxotere for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. The application to the FDA follows the completion of a randomized, parallel-group, open-label, multicenter Phase III clinical trial that evaluated time to progression (TTP) of the disease with combination versus monotherapy docetaxel...

2008-09-08 09:00:08

BRIDGEWATER, N.J., Sept. 8 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the combination of DOXIL(R) (doxorubicin HCl liposome injection) and Taxotere(R) (docetaxel)* for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. The application to the FDA follows the completion of a randomized, parallel-group,...

2008-09-05 09:00:37

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that the first patient has been dosed in its international Phase II randomized controlled trial of palifosfamide (ZIO-201) in patients with soft-tissue sarcoma (STS): This is a Phase II multi-center, parallel group, randomized study of palIfosfamide plus doxorubicin versus doxorubiCin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO). Approximately 100 evaluable subjects are expected to be enrolled in this...

2008-08-14 00:00:11

A TREATMENT for brittle bones has a dramatic effect on breast cancer when combined with chemotherapy, research has shown. Scientists found that the two drugs acted together to slow down the growth of tumours. In mice given the therapy, growing breast tumours were almost stopped in their tracks. A clinical trial is now under way in the UK which could lead to the treatment becoming widely available to patients. Since both drugs are already well established, and only need the terms of...

2008-08-13 21:00:10

By JOHN VON RADOWITZ BREAST cancers sufferers were today given a boost after research revealed that a treatment for brittle bones has a dramatic effect on the disease when combined with chemotherapy, research has shown. Scientists who carried out tests on mice that found that the two drugs acted together to slow down the growth of tumours. The therapy involves the breast cancer chemotherapy agent doxorubicin and the bisphosphonate drug zoledronic acid. And it is now hoped that both...

2008-07-29 09:01:15

CELSION CORPORATION (NASDAQ: CLSN) announced that its docetaxel thermosensitive liposome preclinical study results were presented at the 11th Liposome Research Days Conference during the poster session on July 22, 2008. The well attended presentation provided detailed preclinical results regarding the use of Celsion's temperature sensitive liposome formulation with docetaxel. This novel, patent pending encapsulation of a well known chemotherapeutic agent demonstrates improved anti-tumor...

2008-07-28 18:00:42

PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing novel products based on proven combinations of chemotherapeutic drugs, today announced that it raised in excess of $22.5 million in a Series C private equity financing. All Series B investors participated in the financing and included; Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital. The proceeds will be...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related